For semaglutide doses, the volume loss from dead space at starting doses is proportionally larger, making low dead space syringes especially worthwhile early in the protocol
Common denial reasons include insufficient BMI documentation, missing lifestyle modification records, or not trying required step therapy first
Slowing gastric emptying: GLP-1 also slows down the rate at which the stomach empties its contents into the small intestine
Lack of patient education or awareness: Many patients are unaware of how these medications work, how to manage side effects, or how to navigate the complexities of insurance coverage
Researchers are investigating genetic variants in GLP-1 receptor pathways, gut microbiome profiles, and baseline hormone levels to determine who will respond best to GLP-1 therapy, who might benefit from dual agonists, and who is more prone to side effects